MedTrace Logo

Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study

NCT00983320 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2011-10-05

No results posted yet for this study

Summary

This is a double-blind, randomized, placebo-controlled trial measuring the impact of quetiapine on clinical and experimental measures of pain in fibromyalgia and its biochemical correlates.

Conditions

  • Fibromyalgia

Interventions

DRUG

quetiapine

flexible dosage (50 to 300 mg)

DRUG

placebo

placebo

Sponsors & Collaborators

  • Université de Montréal

    collaborator OTHER

  • Université de Sherbrooke

    lead OTHER

Principal Investigators

  • Serge Marchand, PhD · Université de Sherbrooke

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00983320 on ClinicalTrials.gov